Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The employee equity awards vest over four years, with each installment dependent on continued service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zenas BioPharma (Nasdaq: ZBIO) granted 74,900 restricted stock units to newly hired employees on October 15, 2026, as employment inducements.
The awards, which represent rights to shares of common stock, vest in four equal annual installments: 25% on each of October 15, 2027, 2028, 2029 and 2030. Vesting requires continued service through each applicable date. The Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4), subject to the 2026 Inducement Plan and applicable award agreements.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.74,900 restricted stock units granted to new employees create potential shareholder dilution as awards vest.
Key Figures
- Restricted stock units granted
- 74,900 RSUs
- Inducement awards to newly hired employees
- Vesting schedule
- 4 equal annual installments of 25%
- Scheduled for October 15, 2027, 2028, 2029 and 2030
Historical Context
-
Granted options and RSUs to new employees under the same Nasdaq inducement-grant rule.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on October 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted an aggregate of 74,900 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
The RSUs will vest in four (4) equal installments over a four-year period, with vesting as to twenty-five percent (
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced leadership team with a disciplined global product candidate acquisition approach to identify, acquire and develop product candidates with the potential to deliver clinically meaningful benefits to patients. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb to inhibit the activity of B cells implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may enable sustained control across multiple chronic autoimmune diseases. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a novel, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Contacts:
Investors:
Argot Partners
Zenas@argotpartners.com
Media:
Kristin Ainsworth
SVP, U.S. Commercial Strategy & Corporate Affairs
612.839.6748
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many restricted stock units did Zenas BioPharma grant to new employees?
Zenas BioPharma granted 74,900 restricted stock units to newly hired employees on October 15, 2026, as inducements to enter employment.
When do Zenas BioPharma's October 2026 inducement awards vest?
The awards vest 25% annually on October 15, 2027, October 15, 2028, October 15, 2029 and October 15, 2030. Employees must remain in service through each applicable vesting date.